A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

NCT07106671 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

CRS - Cytokine Release Syndrome
Myeloma

Interventions

DRUG: Siltuximab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China